ArticleFrontiers in pharmacology2026
Regulation of doxorubicin resistance and cellular metabolism by miR-203a-3p via p53 and TAp63 signaling in hepatocellular carcinoma.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Doxorubicin (DOX) is a cornerstone chemotherapeutic drug in the treatment of hepatocellular carcinoma (HCC). However, its efficacy is often limited by the development of drug resistance linked to increased cellular capacity to repair DNA damage. Altered tumor metabolism allows cancer cells to meet increased energy demands for rapid proliferation while evading apoptosis and adapting to therapeutic interventions. MiR-203a-3p is associated with regulating members of the p53 family and has been implicated in regulating chemoresistance and metabolic rewiring in various cancers, yet its role in HCC remains to be elucidated. This study investigated the functional role of miR-203a-3p in response to DOX in HCC cell lines differing in p53 status. HepG2 (wild-type p53) and Huh7 (mutant p53) cells were transfected with miR-203a-3p mimics or inhibitors, alone or in combination with DOX. Cell viability was assessed by MTT assay, and the expression levels of p53 family members and Bax were measured by qPCR. Apoptosis was evaluated by flow cytometry, and mitochondrial function was examined using the Seahorse XFe96 analyzer. MiR-203a-3p expression was significantly higher in DOX-resistant HepG2 cells relative to DOX-sensitive Huh7 cells. In HepG2 cells, miR-203a-3p promoted resistance through p53/Δ133p53-driven survival and enhanced oxidative phosphorylation. In Huh7 cells, it suppressed TAp63/Bax-mediated apoptosis while driving both oxidative phosphorylation and glycolysis, promoting resistance despite the absence of wild-type p53. These findings identify miR-203a-3p as a key modulator of DOX resistance in HCC through coordinated regulation of p53 family expression, apoptotic signaling, and metabolic rewiring, highlighting its potential as a therapeutic target for miRNA-based combination therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.